Tania Nikolcheva

Basel, BS, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled study.

Journal: Lancet (London, England)
Published: February 02, 2026

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Author Correction: Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Journal: NPJ Parkinson's disease
Published: August 13, 2025

Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.

Estimation of and clinical consensus on the meaningful motor progression threshold on MDS-UPDRS Part III.

Journal: Journal of Parkinson's disease
Published: February 20, 2025

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.

A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous prasinezumab in early-stage Parkinson's disease (PADOVA): Rationale, design, and baseline data.

Journal: Parkinsonism & related disorders
Published: November 02, 2024

Biologically defined neuronal synuclein disease as a tool to advance drug development.

Biologically defined neuronal synuclein disease as a tool to advance drug development.

Journal: NPJ Parkinson's disease
Published: October 31, 2024

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Time-to-event analysis mitigates the impact of symptomatic therapy on therapeutic benefit in Parkinson's disease trials.

Journal: NPJ Parkinson's disease
Published: September 13, 2024

Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.

Modeling of Parkinson's Disease Progression and Implications for Detection of Disease Modification in Treatment Trials.

Journal: Journal of Parkinson's disease
Published: July 26, 2024

Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.

Sustained effect of prasinezumab on Parkinson's disease motor progression in the open-label extension of the PASADENA trial.

Journal: Nature medicine
Published: April 07, 2024

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Journal: NPJ digital medicine
Published: February 02, 2024

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease.

Journal: Nature medicine
Published: June 30, 2023

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Trial of Prasinezumab in Early-Stage Parkinson's Disease.

Journal: The New England journal of medicine
Published: August 03, 2022

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

Journal: Frontiers in neurology
Published: May 05, 2021
Showing 1-12 of 18

Last Updated: 09/26/2026